复发难治性霍奇金淋巴瘤治疗研究进展

大多数霍奇金淋巴瘤(HL)可以治愈,但复发难治性HL治疗依旧是研究的难点及重点.大剂量化疗联合自体造血干细胞移植是该类患者的首选方案,但仍存在较高的复发率.第59届美国血液学会年会关于复发难治性HL的治疗进展有许多报道,包括对传统大剂量化疗方案的改进,brentuximab vedotin、nivolumab和pembrolizumab等新药的组合方案,以及伊布替尼、嵌合抗原受体T细胞在HL中的尝试应用等.现结合会议报道就复发难治性HL治疗的最新研究进展进行介绍.

Treatment progress of relapsed and refractory Hodgkin lymphoma

Hodgkin lymphoma (HL) is a highly curable malignancy for most patients, while the treatment of relapsed and refractory HL is still a difficult and important field. A high dose of chemotherapy with autologous stem cell transplantation is treated as the preferred treatment with a high relapse incidence. The 59th American Society of Hematology Annual Meeting reported the recent progress of the treatment of relapsed and refractory HL, including the improvement of traditional high dose chemotherapy regimens, the new drugs or therapies like brentuximab vedotin, nivolumab, pembrolizumab and ibrutinib, and chimeric antigen receptor T-cell. This review focuses on these advances.